Oncogenic and Tumor Suppressor Functions for Lymphoid Enhancer Factor 1 in E2a-/- T Acute Lymphoblastic Leukemia

被引:6
|
作者
Carr, Tiffany [1 ]
McGregor, Stephanie [2 ,8 ]
Dias, Sheila [3 ]
Verykokakis, Mihalis [3 ,9 ]
Le Beau, Michelle M. [4 ]
Xue, Hai-Hui [5 ]
Sigvardsson, Mikael [6 ]
Bartom, Elizabeth T. [7 ]
Kee, Barbara L. [1 ,2 ,3 ]
机构
[1] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA
[2] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA
[4] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[5] Hackensack Univ, Ctr Discovery & Innovat, Med Ctr, Nutley, NJ USA
[6] Lund Univ, Dept Mol Hematol, Lund, Sweden
[7] Northwestern Univ, Dept Biochem & Mol Genet, Chicago, IL 60611 USA
[8] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA
[9] Biomed Sci Res Ctr BSRC Aexander Fleming, Vari, Greece
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
E2a; Lef1; leukemia; thymus; lymphocyte; CELL DEVELOPMENT; TRANSCRIPTION FACTORS; TAL1; COMPLEX; E-PROTEINS; C-MYC; NOTCH1; ACTIVATION; EXPRESSION; RECEPTOR; ROLES;
D O I
10.3389/fimmu.2022.845488
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T lymphocyte acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease affecting T cells at multiple stages of their development and is characterized by frequent genomic alterations. The transcription factor LEF1 is inactivated through mutation in a subset of T-ALL cases but elevated LEF1 expression and activating mutations have also been identified in this disease. Here we show, in a murine model of T-ALL arising due to E2a inactivation, that the developmental timing of Lef1 mutation impacts its ability to function as a cooperative tumor suppressor or oncogene. T cell transformation in the presence of LEF1 allows leukemic cells to become addicted to its presence. In contrast, deletion prior to transformation both accelerates leukemogenesis and results in leukemic cells with altered expression of genes controlling receptor-signaling pathways. Our data demonstrate that the developmental timing of Lef1 mutations impact its apparent oncogenic or tumor suppressive characteristics and demonstrate the utility of mouse models for understanding the cooperation and consequence of mutational order in leukemogenesis.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia
    Nagel, Stefan
    Venturini, Letizia
    Meyer, Corinna
    Kaufmann, Maren
    Scherr, Michaela
    Drexler, Hans G.
    Macleod, Roderick A. F.
    LEUKEMIA & LYMPHOMA, 2011, 52 (02) : 290 - 297
  • [2] LEF1 Is a Tumor Suppressor in T Cell Acute Lymphoblastic Leukemia
    Gutierrez, Alejandro
    Sanda, Takaomi
    Winter, Stuart
    Larson, Richard S.
    Silverman, Lewis B.
    Hunger, Stephen P.
    Sallan, Stephen E.
    Look, A. Thomas
    BLOOD, 2008, 112 (11) : 1300 - 1301
  • [3] YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia
    Li, Huan
    Zhang, Danlan
    Fu, Qiuxia
    Wang, Shang
    Wang, Zhongyuan
    Zhang, Xin
    Chen, Xin
    Zhu, Xiaoyu
    An, Na
    Chen, Yun
    Zhou, Liang
    Lu, Desheng
    Zhao, Na
    BLOOD ADVANCES, 2023, 7 (17) : 4874 - 4885
  • [4] JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia
    Mansour, Marc R.
    He, Shuning
    Li, Zhaodong
    Lobbardi, Riadh
    Abraham, Brian J.
    Hug, Clemens
    Rahman, Sunniyat
    Leon, Theresa E.
    Kuang, You-Yi
    Zimmerman, Mark W.
    Blonquist, Traci
    Gjini, Evisa
    Gutierrez, Alejandro
    Tang, Qin
    Garcia-Perez, Laura
    Pike-Overzet, Karin
    Anders, Lars
    Berezovskaya, Alla
    Zhou, Yi
    Zon, Leonard I.
    Neuberg, Donna
    Fielding, Adele K.
    Staal, Frank J. T.
    Langenau, David M.
    Sanda, Takaomi
    Young, Richard A.
    Look, A. Thomas
    JOURNAL OF EXPERIMENTAL MEDICINE, 2018, 215 (07): : 1929 - 1945
  • [5] RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia
    Choi, AHyun
    Illendula, Anuradha
    Pulikkan, John A.
    Roderick, Justine E.
    Tesell, Jessica
    Yu, Jun
    Hermance, Nicole
    Zhu, Lihua Julie
    Castilla, Lucio H.
    Bushweller, John H.
    Kelliher, Michelle A.
    BLOOD, 2017, 130 (15) : 1722 - 1733
  • [6] Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia
    Sanghvi, Viraj R.
    Mavrakis, Konstantinos J.
    Van der Meulen, Joni
    Boice, Michael
    Wolfe, Andrew L.
    Carty, Mark
    Mohan, Prathibha
    Rondou, Pieter
    Socci, Nicholas D.
    Benoit, Yves
    Taghon, Tom
    Van Vlierberghe, Pieter
    Leslie, Christina S.
    Speleman, Frank
    Wendel, Hans-Guido
    SCIENCE SIGNALING, 2014, 7 (352)
  • [7] TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia
    Sanda, Takaomi
    Leong, Wei Zhong
    EXPERIMENTAL HEMATOLOGY, 2017, 53 : 7 - 15
  • [8] Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia
    W S Liau
    S H Tan
    P C T Ngoc
    C Q Wang
    V Tergaonkar
    H Feng
    Z Gong
    M Osato
    A T Look
    T Sanda
    Leukemia, 2017, 31 : 1798 - 1807
  • [9] Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia
    Liau, W-S
    Tan, S. H.
    Ngoc, P. C. T.
    Wang, C. Q.
    Tergaonkar, V.
    Feng, H.
    Gong, Z.
    Osato, M.
    Look, A. T.
    Sanda, T.
    LEUKEMIA, 2017, 31 (08) : 1798 - 1807
  • [10] The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia
    Tan, Shi Hao
    Leong, Wei Zhong
    Phuong Cao Thi Ngoc
    Tan, Tze King
    Bertulfo, Fatima Carla
    Lim, Mei Chee
    An, Omer
    Li, Zhenhua
    Yeoh, Allen Eng Juh
    Fullwood, Melissa J.
    Tenen, Daniel G.
    Sanda, Takaomi
    BLOOD, 2019, 134 (03) : 239 - 251